Switch theme
Sign up to access all valuation multiples
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
2006
126
LTM Revenue $336M
LTM EBITDA $153M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Protagonist Therapeutics has a last 12-month revenue of $336M and a last 12-month EBITDA of $153M.
In the most recent fiscal year, Protagonist Therapeutics achieved revenue of $434M and an EBITDA of $256M.
Protagonist Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Protagonist Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $60.0M | $434M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$90.3M | $256M | XXX | XXX | XXX |
| EBITDA Margin | -151% | 59% | XXX | XXX | XXX |
| Net Profit | -$127M | -$79.0M | XXX | XXX | XXX |
| Net Margin | -212% | -18% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Protagonist Therapeutics's stock price is $45.
Protagonist Therapeutics has current market cap of $2.8B, and EV of $2.4B.
See Protagonist Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.8B | XXX | XXX | XXX | XXX | $2.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Protagonist Therapeutics has market cap of $2.8B and EV of $2.4B.
Protagonist Therapeutics's trades at 7.0x LTM EV/Revenue multiple, and 15.4x LTM EBITDA.
Analysts estimate Protagonist Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Protagonist Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | 9.2x | XXX | XXX | XXX |
| P/E | 10.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 12.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpProtagonist Therapeutics's NTM/LTM revenue growth is -69%
Protagonist Therapeutics's revenue per employee for the last fiscal year averaged $3.4M, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Protagonist Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Protagonist Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Protagonist Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 624% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 59% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -383% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -10% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $3.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 32% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 42% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Protagonist Therapeutics acquired XXX companies to date.
Last acquisition by Protagonist Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Protagonist Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Protagonist Therapeutics founded? | Protagonist Therapeutics was founded in 2006. |
| Where is Protagonist Therapeutics headquartered? | Protagonist Therapeutics is headquartered in United States of America. |
| How many employees does Protagonist Therapeutics have? | As of today, Protagonist Therapeutics has 126 employees. |
| Who is the CEO of Protagonist Therapeutics? | Protagonist Therapeutics's CEO is Dr. Dinesh V. Patel, PhD. |
| Is Protagonist Therapeutics publicy listed? | Yes, Protagonist Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Protagonist Therapeutics? | Protagonist Therapeutics trades under PTGX ticker. |
| When did Protagonist Therapeutics go public? | Protagonist Therapeutics went public in 2016. |
| Who are competitors of Protagonist Therapeutics? | Similar companies to Protagonist Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Protagonist Therapeutics? | Protagonist Therapeutics's current market cap is $2.8B |
| What is the current revenue of Protagonist Therapeutics? | Protagonist Therapeutics's last 12-month revenue is $336M. |
| What is the current EBITDA of Protagonist Therapeutics? | Protagonist Therapeutics's last 12-month EBITDA is $153M. |
| What is the current EV/Revenue multiple of Protagonist Therapeutics? | Current revenue multiple of Protagonist Therapeutics is 7.0x. |
| What is the current EV/EBITDA multiple of Protagonist Therapeutics? | Current EBITDA multiple of Protagonist Therapeutics is 15.4x. |
| What is the current revenue growth of Protagonist Therapeutics? | Protagonist Therapeutics revenue growth between 2023 and 2024 was 624%. |
| Is Protagonist Therapeutics profitable? | Yes, Protagonist Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
